REFINE-Lung, NCT05085028: A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1750 | Europe | Pembrolizumab 25 MG/ML [Keytruda] | Imperial College London, National Institute for Health Research, United Kingdom, Medical Research Council, University College, London | Lung Cancer, Nonsmall Cell | 05/27 | 05/27 | | |
| Active, not recruiting | 2 | 88 | Europe | Niraparib Oral Product, Zejula, Active Symptom Control | University Hospital Southampton NHS Foundation Trust, University of Southampton, British Lung Foundation | Mesothelioma, Malignant | 12/24 | 12/24 | | |
